| Document |
Document Title |
|
WO/2019/016555A1 |
Novel peptides and the uses thereof, in particular for use in male contraception or for use in the treatment of male infertility.
|
|
WO/2019/018348A1 |
Ammonia oxidizing microorganism preparations for delivery to the urogenital system, kits including ammonia oxidizing preparations for delivery to the urogenital system, and devices for administering ammonia oxidizing preparations to the ...
|
|
WO/2019/016074A1 |
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
|
|
WO/2019/017384A1 |
The present invention provides a peptide having a structure in which a portion of a dominant-negative peptide of BIG3 which inhibits interaction between BIG3 and PHB2, is replaced by at least two stapling structures. The peptide accordin...
|
|
WO/2019/013637A1 |
The present invention relates to a mixture of strains of Lactobacillus crispatus, which mixture comprises strains that have a different carbohydrate degradation profile, comprising at least one strain of L. crispatus that is able to degr...
|
|
WO/2019/012199A1 |
The food supplement according to the present invention for protecting female and male fertility intended for oral administration, helping reduce both oxygenated free radicals, which cause DNA damage, and homocystine, therefore reducing t...
|
|
WO/2019/009739A1 |
The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and preventi...
|
|
WO/2019/007299A1 |
Disclosed are a salt and a polymorph of a benzopyrimidinone compound and a pharmaceutical composition and the use thereof. In particular, disclosed are a hydrochloride of a benzopyrimidinone compound as shown in the following formula, (I...
|
|
WO/2019/008025A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
WO/2019/004877A1 |
The group of inventions relates to medicine and veterinary science, and more particularly to medical and veterinary gynaecology. Proposed is the use of 9-phenyl-sym-octahydroselenoxanthene as an agent for treating female infertility and ...
|
|
WO/2019/003053A1 |
The present invention relates to an association comprising molecular oxygen and hyaluronic acid for use in the topical treatment of vaginal disorders and, more preferably, for the treatment of vaginal dryness and vulvovaginal atrophy.
|
|
WO/2019/000504A1 |
Provided are a PDE 5 and a preparation method therefor, and application of the PDE 5 to preparation of drugs used for treating, alleviating or preventing PDE 5-related diseases or disease states of mammals. The structural formula of the ...
|
|
WO/2018/236680A1 |
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.
|
|
WO/2018/233728A1 |
Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain ...
|
|
WO/2018/234342A1 |
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
|
|
WO/2018/233509A1 |
Disclosed is an abortion drug. The abortion drug comprises a Phaseolus vulgaris phytohemagglutinin, and the concentration of the Phaseolus vulgaris phytohemagglutinin in the abortion drug is 40-60 mg/ml. The abortion drug may comprise a ...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/227829A1 |
A traditional Chinese medicine, comprising bulk materials of: 12 parts of Root of Ligulilobe Sage, 10 parts of Odoriferous Rosewood, 15 parts of Dodder Seed, 10 parts of Himalayan Teasel Root, 10 parts of Chinese Taxillus Herb, 20 parts ...
|
|
WO/2018/231739A1 |
The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
|
|
WO/2018/224498A1 |
The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Mülleria...
|
|
WO/2018/224497A1 |
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) ...
|
|
WO/2018/226769A1 |
Compounds of Formula (I) that antagonize vasopressin receptors, particularly the Via receptor. The compounds are useful for treating e.g. neuropsychological disorders, such as e.g. anxiety, depression and schizophrenia. Preferred compoun...
|
|
WO/2017/202817A9 |
The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,
3-triazol-4-yl)methanone compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds...
|
|
WO/2018/221521A1 |
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...
|
|
WO/2018/219747A1 |
The present document is directed to a pharmaceutical composition comprising at least one non-ionic cellulose ether, wherein said composition has a viscosity of 35000 cP or more, an osmolality of from about 10 to about 300 mOsmol/kg, and ...
|
|
WO/2018/221966A1 |
The present invention relates to a pharmaceutical composition for prevention or treatment of bone-related diseases, which promotes the differentiation of preosteoblasts into osteoblasts to induce the formation of calcified nodules and si...
|
|
WO/2018/221679A1 |
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.
|
|
WO/2018/220126A1 |
A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).
|
|
WO/2018/216228A1 |
The purpose of the present invention is to establish, as one of bladder regenerative medical techniques, novel treatment which transplants a bone marrow-derived cell structure into a bladder and attempts to regenerate a functional bladde...
|
|
WO/2018/215433A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-...
|
|
WO/2018/069467A9 |
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the ...
|
|
WO/2018/214736A1 |
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...
|
|
WO/2018/211276A1 |
The invention relates to a method of reducing sperm motility or of contraception in a subject, said method comprising the step of administering to said subject an effective amount of a compound of formula (I), a stereoisomer, tautomer, p...
|
|
WO/2018/209809A1 |
The present application relates to a polycrystalline mesylate of a phosphodiesterase type 5 inhibitor. The chemical name of the phosphodiesterase type 5 inhibitor is 5-[2-ethoxy-5-(4-methylpiperazin-1-yl-thiocarbonyl)phenyl]-1
-methyl-3-...
|
|
WO/2018/213125A1 |
Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metaboli...
|
|
WO/2018/212136A1 |
The present invention addresses the problem of providing: an antibody having an internalization activity of binding to CDH6; an antibody-drug conjugate consisting of the aforesaid antibody and a drug having an antitumor activity; a medic...
|
|
WO/2018/212256A1 |
[Problem] To provide a pharmaceutical agent for treatment of pain associated with a gynecological disorder and/or treatment of a structural lesion caused by a gynecological disorder. [Solution] A therapeutic agent for pain associated wit...
|
|
WO/2018/207736A1 |
The present disclosure relates to a method for introducing a polynucleotide to a male germ cell or Sertoli cell, the method including injection of an adeno-associated virus vector containing the polynucleotide to a testicle of a vertebrate.
|
|
WO/2018/206959A1 |
The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as m...
|
|
WO/2018/206956A1 |
The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists a...
|
|
WO/2018/208826A1 |
A method of enhancing sperm fertility is described herein. The method includes contacting sperm with hydroxyurea. A composition is disclosed that includes sperm, hydroxyurea, and a buffer. Methods, kits, and compositions for enhancing sp...
|
|
WO/2018/205191A1 |
An industrial preparation method suitable for extracting four types of quassin ingredient from eurycoma longifolia plants, and an application for preparing products. Ultrasonic countercurrent water extraction and silica gel-low boiling p...
|
|
WO/2018/206923A1 |
The invention relates to multicomponent pharmaceutical compositions which comprise a selective serotonin reuptake inhibitor (SSRI).
|
|
WO/2018/201579A1 |
Medicated chicken, prepared by employing the following ingredients: 500-1000 g of chicken, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiemalis, 3-9 g of...
|
|
WO/2018/201576A1 |
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...
|
|
WO/2018/201578A1 |
Medicated hare or rabbit meat, prepared by employing the following ingredients: 500-1000 g of hare or rabbit meat, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equ...
|
|
WO/2018/201571A1 |
A traditional Chinese medicine composition for treating dysmenorrhea, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba...
|
|
WO/2018/201577A1 |
A health-promoting fruit wine, prepared by employing the following ingredients: 400-600 g of grape wine, 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of Herba Equiseti Hiem...
|
|
WO/2018/201570A1 |
A traditional Chinese medicine composition for treating uterine prolapse, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of H...
|
|
WO/2018/199748A1 |
The present invention pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. The invention also pertains to compositions comprising a calcium b...
|
